Passage Bio Stock

passagebio.comHealthcareFounded: 2018Funding to Date: $225.5MM

Passage Bio is a genetic medicines company focused on developing a deep pipeline of adeno-associated virus (AAV) delivered therapeutics for the treatment of rare monogenic central nervous system disorders (CNS).

Register for Details

For more details on financing and valuation for Passage Bio, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Click here to log in

Enterprise Value (based on primary financings)

Enterprise Value

View Enterprise Value for Passage Bio.

Register Today

Team

Management Team

Jill Quigley JD
Chief Operating Officer, Operations
Gary Romano Ph.D
Chief Medical Officer
Tadataka Yamada MD
Co-Founder & Chairman
Richard Morris
Chief Financial Officer, Finance
James Wilson Ph.D
Co-Founder & Chief Scientific Advisor
Bruce Goldsmith Ph.D
Chief Executive Officer & Board Member
Alex Fotopoulos
Chief Technology Officer, Technology
Stephen Squinto Ph.D
Co-Founder, Board Member & Acting Head of R&D

Board Members

Bruce Goldsmith Ph.D
Sandip Kapadia
Thomas Woiwode Ph.D
Versant Venture Management
Liam Ratcliffe Ph.D
Stephen Squinto Ph.D
Patrick Heron
Frazier Healthcare Partners
Saqib Islam JD
Tadataka Yamada MD

Other companies like Passage Bio in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$317.32MM
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$885.01MM
Sector
 
 

News

Gene therapy developer Passage Bio priced its initial public offering at $18 per share, raising $216 million---72 percent more than it originally planned
Longtime biopharmaceutical executive Tachi Yamada helped keep the work of gene therapy pioneer James Wilson alive 20 years ago when Wilson was mired in